Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 0.62 |
| ▸ | ATXN2 | Q99700 | 9/20 | 0.62 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16961602 | 0.84 | ATXN2 (0.53) | ENPP2ATXN2 | |
| SCHEMBL16052911 | 0.83 | ENPP2 (0.72) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL16053306 | 0.78 | CA2 (0.63) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL16052857 | 0.78 | CA2 (0.63) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL15541183 | 0.77 | ATXN2 (1.00) | ENPP2ATXN2 | |
| SCHEMBL22957147 | 0.76 | ATXN2 (0.61) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL16053213 | 0.75 | ENPP2 (0.60) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL21485424 | 0.75 | ENPP2 (0.60) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL16053211 | 0.75 | ENPP2 (0.60) | ENPP2ATXN2CA2CA1CA9 | |
| SCHEMBL16962328 | 0.75 | ENPP2 (0.42) | ENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913745-B2 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-02-09 | — | — | US | claimed |
| EP-2970256-B1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-23 | — | — | EP | claimed |
| US-20180258095-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-09-13 | — | — | US | claimed |
| EP-2970256-A1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | claimed |
| US-20150376194-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | claimed |
| WO-2014139978-A1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | claimed |
| US-10913745-B2 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-2970256-B1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-20180258095-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-09-13 | — | — | US | disclosed |
| EP-2970256-A1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376194-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014139978-A1 | NEW OCTAHYDRO-PYRROLO[3,4-C]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913745-B2 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | ENPP2, TPX2, PRAP1 | ENPP2 1/4885ATXN2 233/4885CA2 2616/4885 |
| US-20180258095-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | ENPP2, TPX2, UACA | ENPP2 1/4885ATXN2 305/4885CA2 2874/4885 |
| US-20150376194-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | ENPP2, TPX2, UACA | ENPP2 1/4885ATXN2 305/4885CA2 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.